中国医药科学Issue(3)：83-84,127,3.
头孢哌酮舒巴坦钠在院内感染应用的成本效果分析
The cost-effectiveness analysis of cefoperazone sulbactam for treating nosocomial infections
朱林1
作者信息
- 1. 河南省驻马店市第一人民医院，河南驻马店463000
- 折叠
摘要
Abstract
Objective To discuss the cost-effectiveness of cefoperazone sulbactam for treating nosocomial infections. Methods 90 cases of nosocomial infection in hospitalized patients under treatment were equally divided into group A, B and C group of 30 cases, A group were given with cefoperazone sulbactam treatment, B group were given with cefazolin treatment, C group were given with cefodizime treatment. Results The effective rate of the A group was 90.0%, B group was 70.0%, C group was 100.0% and compared among the three groups had statistically difference (P<0.05). The medical costs compared among the three groups were had statistically difference(P<0.05). A group of C/E valus was 26.80, B group was 39.95, C group was 35.22 that compared the difference had statistically significantly difference (P < 0.05). Conclusion Cefoperazone sulbactam sodium in the treatment of nosocomial infections has costs less and high efficiency, and thus has better cost-effectiveness.关键词
头孢哌酮舒巴坦钠/院内感染/成本效果Key words
Cefoperazone sulbactam/Nosocomial infections/Cost-effectiveness分类
医药卫生引用本文复制引用
朱林..头孢哌酮舒巴坦钠在院内感染应用的成本效果分析[J].中国医药科学,2014,(3):83-84,127,3.
